BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a hold rating to a strong-buy rating in a research note published on Saturday.

Several other equities analysts also recently weighed in on the company. Cantor Fitzgerald raised their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. JPMorgan Chase & Co. began coverage on BioCryst Pharmaceuticals in a research report on Monday, July 13th. They set a “neutral” rating and a $12.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Wedbush dropped their price target on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, Needham & Company LLC dropped their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.60.

BioCryst Pharmaceuticals Trading Up 0.9%

Shares of BCRX opened at $9.38 on Friday. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.22. The firm has a market capitalization of $2.38 billion, a P/E ratio of -6.25 and a beta of 0.55. The firm’s 50-day moving average is $9.33 and its two-hundred day moving average is $8.71.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. The company had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company’s revenue for the quarter was up 33.6% on a year-over-year basis. During the same period last year, the firm earned $0.15 EPS. Analysts predict that BioCryst Pharmaceuticals will post -2.44 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BCRX. Phocas Financial Corp. acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth $1,956,000. Vanguard Group Inc. lifted its position in shares of BioCryst Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after acquiring an additional 482,494 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter valued at $14,880,000. Perceptive Advisors LLC boosted its stake in shares of BioCryst Pharmaceuticals by 135.1% during the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after acquiring an additional 4,271,504 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in BioCryst Pharmaceuticals by 21.4% during the 4th quarter. BNP Paribas Financial Markets now owns 2,542,714 shares of the biotechnology company’s stock worth $19,833,000 after purchasing an additional 448,436 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.